Associated Papers
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
Pfeil AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
Pfeil AJ et al.
Biorxiv : the Preprint Server for Biology, 2025
Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors.
Clavaín L et al.
Oncogene, 2023
36476833 (PubMed )
Supplement: 41388_2022_2563_MOESM1_ESM.pdf
Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.
Mota A et al.
Oncogene, 2022
35145232 (PubMed )
Supplement: 41388_2022_2221_MOESM2_ESM.pdf
Select a paper to view details